As an ophthalmologist with more than 20 years of expertise, I have been primarily committed to the study and treatment of retinal diseases. My main interest is on Age-related Macular Degeneration (AMD), but I have also significant experience on the diagnosis and management of other retinal problems, such as retinal vein occlusion (RVO), pathologic myopia, among others. I daily combine clinical care with clinical research, teaching and leadership activities, which allows me to reach my goals of developing a strong scientific activity based on clinical practice. These activities take primarily place at the Faculty of Medicine of University of Coimbra and at the Department of Ophthalmology of the University Hospital of Coimbra. I also have a strong collaboration with the Association for Innovation and Biomedical Research on Light and Image (AIBILI), Coimbra, as a physician and a researcher. My broad experience in research includes the participation in more than 70 clinical trials and projects, more than 40 of them as Principal Investigator. With the goal of contributing to the better understanding of retinal diseases, their prevention, risk factors and their innovative treatment, most of these studies were primarily focused on AMD. For example, I participated in several multicenter clinical trials with different therapies, such as verteporfin photodynamic therapy (PDT), anti-VEGF injections and treatment with corticosteroids. My main areas of research include: early markers and risk factors of AMD progression, including imaging, genetics and metabolomics; epidemiology of AMD; characterization of food habits in the Portuguese population and correlation with AMD prevalence; and polypoidal choroidal neovascularization. In all these fields I have been particularly involved in developing investigator-driven clinical trials. As a clinician-scientist, my research is also focused on identifying the sequence of changes in the chorioretinal interface that lay the path for the development of choroidal neovascularization (CNV), and the progression from early to late AMD. My goal is to identify the morphological features that define the earliest identifiable CNV lesion and to evaluate the sensitivity of quantitative imaging analysis compared to the conventional clinical exam.